Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
1don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback